TNF and inflammatory bowel disease: Soteria® and PhloralTM [249] platform technologies are currently being investigated for sustained release colon tissue delivery of anti-TNF-α mAbs to provide a novel oral treatment for chronic inflammatory diseases such as inflammatory bowel disease (IBD).